FocalTherics (NASDAQ:FOCL) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of FocalTherics (NASDAQ:FOCL) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

A number of other analysts have also recently weighed in on FOCL. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research note on Tuesday, August 25th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Finally, Mizuho began coverage on FocalTherics in a research note on Friday, July 17th. They issued an “outperform” rating and a $15.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.67.

FocalTherics Stock Down 21.9%

NASDAQ FOCL opened at $3.32 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.60 and a debt-to-equity ratio of 1.79. The business’s 50 day moving average price is $4.23. The firm has a market cap of $124.60 million, a PE ratio of -3.39 and a beta of -0.02. FocalTherics has a 52 week low of $1.82 and a 52 week high of $6.40.

FocalTherics (NASDAQ:FOCL) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.08. FocalTherics had a negative net margin of 59.77% and a negative return on equity of 396.45%. The company had revenue of $9.83 million for the quarter. On average, equities research analysts expect that FocalTherics will post -0.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director David R. Horn purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $47,500. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Fran Schulz purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director directly owned 15,100 shares of the company’s stock, valued at $71,725. This represents a 196.08% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 116,000 shares of company stock worth $551,000. 10.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On FocalTherics

An institutional investor recently raised its position in FocalTherics stock. Rock Springs Capital Management LP increased its position in FocalTherics (NASDAQ:FOCL) by 7.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,378,000 shares of the company’s stock after acquiring an additional 91,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.68% of FocalTherics worth $5,126,000 as of its most recent SEC filing. 62.74% of the stock is owned by institutional investors and hedge funds.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.